Table 1. Patient Characteristics Including Estimates and Confidence Intervals.
| Characteristic | No. (%) | Categorical variables, OR (95% CI) | Continuous variables, difference (95% CI)a | |
|---|---|---|---|---|
| Patients with no ORN (n = 109) | Patients with ORN (n = 13) | |||
| Age, y | NA | 3.8 (−4.3 to 12) | ||
| Median (range) | 65 (21 to 96) | 62 (37 to 87) | ||
| Mean (SD) | 63 (13) | 59 (13) | ||
| Sex | ||||
| Female | 41 (91) | 4 (9) | 1 [Reference] | NA |
| Male | 68 (88) | 9 (12) | 1.36 (0.41 to 5.26) | NA |
| Primary sites | ||||
| Oral cavity | 61 (88) | 8 (12) | 1 [Reference] | NA |
| Oropharynx | 48 (91) | 5 (9) | 0.79 (0.23 to 2.54) | NA |
| Histology | ||||
| ACC | 13 (87) | 2 (13) | 1 [Reference] | NA |
| Others | 6 (75) | 2 (25) | 2.17 (0.22 to 22.0) | NA |
| SCC | 90 (91) | 9 (9) | 0.65 (0.15 to 4.57) | NA |
| T category | ||||
| T0-Tx/T1-T2 | 72 (91) | 7 (9) | 1 [Reference] | NA |
| T3-T4 | 30 (83) | 6 (17) | 2.06 (0.62 to 6.70) | NA |
| Unknown | 7 | 0 | NA | NA |
| N category | ||||
| N0-N1/Nx | 63 (85) | 11 (15) | 1 [Reference] | NA |
| N2-N3 | 39 (95) | 2 (5) | 0.29 (0.04 to 1.17) | NA |
| Unknown | 7 | 0 | NA | NA |
| Hypertension | ||||
| No | 68 (92) | 6 (8) | 1 [Reference] | NA |
| Yes | 41 (85) | 7 (15) | 1.93 (0.60 to 6.39) | NA |
| Diabetes | ||||
| No | 97 (90) | 11 (10) | 1 [Reference] | NA |
| Yes | 12 (86) | 2 (14) | 1.47 (0.21 to 6.38) | NA |
| Smoking history | ||||
| Never | 47 (89) | 6 (11) | 1 [Reference] | NA |
| Former | 62 (90) | 7 (10) | 0.88 (0.28 to 2.91) | NA |
| Concurrent chemotherapy | ||||
| No | 63 (90) | 7 (10) | 1 [Reference] | NA |
| Yes | 46 (88) | 6 (12) | 1.17 (0.36 to 3.76) | NA |
| Type of radiation | ||||
| IMRT + proton boost | 8 (80) | 2 (20) | 1 [Reference] | NA |
| Proton only | 95 (90) | 11 (10) | 0.46 (0.10 to 3.32) | NA |
| Quad shot | 6 (100) | 0 | 0.00 | NA |
| Radiation dose, GyRBE | NA | −1.9 (−13 to 8.8) | ||
| Median (range) | 66 (6 to 76) | 66 (20 to 76) | ||
| Mean (SD) | 58 (18) | 60 (17) | ||
| Dose by radiation type | ||||
| Proton only | 66 (20 to 76) | 66 (60 to 76) | NA | NA |
| IMRT + proton boost | 12 (6 to 40) | 23 (20 to 26) | NA | NA |
| Quad shot | 14 (13 to 44) | NA | NA | NA |
| Pre PRT-dental evaluation | ||||
| No | 68 (91) | 7 (9) | 1 [Reference] | NA |
| Yes | 41 (38) | 6 (46) | 1.42 (0.43 to 4.57) | NA |
| HPV 16+ | ||||
| No | 62 (89) | 8 (11) | 1 [Reference] | NA |
| Yes | 43 (90) | 5 (10) | 0.90 (0.26 to 2.89) | NA |
| Unknown | 4 | 0 | NA | NA |
Abbreviations: ACC, adenoid cystic carcinoma; GyRBE, gray relative biological effectiveness; HPV 16+, human papillomavirus 16–positive status; IMRT, intensity-modulated radiation therapy; N, node; NA, not applicable; OR, odds ratio; ORN, osteoradionecrosis; PRT, proton radiation therapy; SCC, squamous cell carcinoma; T, tumor.
a
Difference in means.